Immunocore Q3 Sales Dip to $102.2M; TEBE-AM Data Pushed to Q2 2027
IMCR is trading near its 52-week low of $27.5 (0.7% above the low).
Summary
Immunocore reported Q3 KIMMTRAK sales of $102.2 million, down slightly year over year but up about 10% on an underlying basis, and said TEBE-AM topline overall survival data is now expected in Q2 2027 rather than by end-2026. Cash of $901.3 million covers the pipeline.
Key Events · Earnings and Guidance · IMCR
-
Q3 KIMMTRAK Sales Slip to $102.2M
Net product sales fell from $103.7 million in Q3 2025; the company attributes the decline to US wholesaler stocking in Q2 2026 and one extra US sales week in Q3 2025, and says underlying growth was about 10%.
-
TEBE-AM Data Pushed to Q2 2027
The Phase 3 trial in previously treated advanced cutaneous melanoma completed enrollment of 540 patients, but topline overall survival data is now expected in Q2 2027, versus the end-of-2026 expectation in the prior quarterly baseline.
-
Q3 Net Loss Widens to $14.2M
Net loss was $14.2 million ($0.28 per share) versus $0.2 million ($0.00) a year earlier, driven by R&D of $74.7 million and SG&A of $40.5 million; nine-month net loss narrowed to $2.1 million.
-
Cash of $901.3M Funds Pipeline
Cash, cash equivalents and marketable securities stood at $901.3 million at September 30, 2026, up from $864.2 million at year-end 2025, though the company expects to pay roughly $120 million in sales-related rebate accruals in Q4 2026.
Analysis · IMCR · Life Sciences
Q3 KIMMTRAK sales slipped to $102.2 million from $103.7 million a year earlier, though management says underlying growth was about 10% once US wholesaler stocking and an extra week in the prior-year quarter are stripped out. The bigger news is timing: topline overall survival data from the TEBE-AM trial in previously treated cutaneous melanoma is now expected in Q2 2027, later than the end-of-2026 expectation carried in the last quarterly baseline. With the stock near its 52-week low, that delay removes the nearest value-inflection point and pushes the key catalyst out by roughly two quarters. The balance sheet is the offset — $901.3 million in cash and securities funds the three Phase 3 trials and the autoimmune programs without an obvious near-term raise.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, IMCR was trading at $27.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $27.50 to $40.71. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.